Sagimet Biosciences Inc. Revenue
Sagimet Biosciences Inc. (SGMT) reported Revenue of $2.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-03-12
- Sagimet Biosciences Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-12-31 was $0.00.
- Sagimet Biosciences Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-09-30 was $2.00M.
- Sagimet Biosciences Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.00M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 1 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $2.00M derived: sum of 2 quarters · filed 2025-03-12 | $2.00M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-14 | $2.00M 10-Q · filed 2024-11-14 | |||
| 2023-07-31 | $2.00M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |